Chemed Aktie - CXM

Professionelle Tools für Privatanleger.

Premium

Current Price

490,00

Gebot

488,00

Fragen

496,00

Volumen

0,00

0,00 Tagesbereich 0,00

480,00 52-Wochen-Bereich 585,00

Handelsende

490,00

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported today that its Cardium Biologics division provided...

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to launch a new premium advanced skin...

Cardium Reports on Exchange Listing With NYSE AMEX

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported that it received notification from the staff of the...

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on recent clinical findings published in the...

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

SAN DIEGO, Dec. 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced a presentation titled, "Phase 2b Study of GAM501...

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that its wholly-owned subsidiary, Tissue...

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its third quarter...

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to submit a 510(k) premarket...

Cardium Completes $6.0 Million Registered Direct Offering

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed its previously...

Cardium Announces $6.0 Million Registered Direct Offering

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced a registered direct offering of common stock...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	-75	-13.2743362832	565	575	515	13	538.67924528	DE
12	-55	-10.0917431193	545	585	515	10	538.78419453	DE
26	-55	-10.0917431193	545	585	480	12	525.83217753	DE
52	-45	-8.41121495327	535	585	480	10	523.5488959	DE
156	-45	-8.41121495327	535	585	480	10	523.5488959	DE
260	-45	-8.41121495327	535	585	480	10	523.5488959	DE

CXM - Frequently Asked Questions (FAQ)

What is the current Chemed share price?

The current share price of Chemed is 490,00 €

What is the 1 year trading range for Chemed share price?

Chemed has traded in the range of 480,00 € to 585,00 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
08XPony AI Inc	9,20 € (49,59%)	32,95k
JJ80ASEP Medical Holdings Inc	0,299 € (36,22%)	7,22k
7XTXTM Inc	0,0392 € (29,80%)	1,06k
PLUNPlug Power Inc	0,9246 € (29,37%)	3,67M
CR6AWolfspeed Inc	3,677 € (28,03%)	414,31k
D0TLegible Inc	0,006 € (-47,83%)	1,5k
3SHShunfeng International Clean Energy Limited	0,0014 € (-36,36%)	60k
4E2Relmada Therapeutics Inc	0,386 € (-32,28%)	13,97k
E3O1Nexoptic Technology Corp	0,0055 € (-31,25%)	26,25k
2QD0Troubadour Resources Inc	0,02 € (-26,47%)	20
PLUNPlug Power Inc	0,9246 € (29,37%)	3,67M
D7GNel ASA	0,2002 € (0,30%)	3,06M
1XNAYnvisible Interactive Inc	0,131 € (19,63%)	1,46M
5YWBattery X Metals Inc	0,148 € (6,47%)	1,28M
TKAThyssenkrupp AG	10,05 € (1,93%)	1,18M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Chemed Corp (CXM)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

CXM Neueste Nachrichten

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

Cardium Reports on Exchange Listing With NYSE AMEX

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

Cardium Completes $6.0 Million Registered Direct Offering

Cardium Announces $6.0 Million Registered Direct Offering

CXM - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Chemed Corp (CXM) Börsenkurse

Chemed Corp (CXM)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

CXM Neueste Nachrichten

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

Cardium Reports on Exchange Listing With NYSE AMEX

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

Cardium Completes $6.0 Million Registered Direct Offering

Cardium Announces $6.0 Million Registered Direct Offering

CXM - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen